Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Localized Immune Modulation to Preserve Islet Graft Function
EF 2023-24
Résumé
Islet cell transplantation to treat type 1 diabetes has been proven to be a viable and effective method to establish normal blood glucose levels in patients. However, an issue faced with islet cell transplantation is that the standard practice of infusing the cells into liver leads to gradual deterioration of the graft. Additionally, islet cells transplanted into the liver are difficult to recover and monitor after surgery. Once transplanted, the islet cells face the inflammatory and adaptive immune response from the host body. Hence, recipients of islet cell transplantation must undergo lifelong immunosuppression. A subcutaneous transplant site (under the skin) is appealing due to its non-invasive nature and being easily accessible for post-transplant monitoring. A subcutaneous device-less (DL) transplant method has been developed to precondition the transplant site by improving the vascularization and reducing inflammation to make the environment more favourable for the islet cells. An approach being investigated to tackle the issue of systemic immunosuppression after transplantation is the localized delivery of drugs through polymer-derived microspheres. These microspheres allow for the localized delivery of a desired drug and allows for a gradual release due to its biocompatibility and biodegradable properties. The project aims to develop a subcutaneous transplantation site that is immuno-suppressive free through the use of the device-less method and microspheres. Further testing will be done to evaluate the efficacy of other drugs and possible drug combinations. If proven effective the subcutaneous transplant site and microspheres together could eliminate the need for systemic immunosuppression and allow for better function and monitoring of the graft.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506504
Name
Ma Ivan J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Localized Immune Modulation to Preserve Islet Graft Function
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Therapy; Engraftment; Graft Rejection; Immunosuppression; Islet Transplantation; Localized Drug Delivery; Microparticles; Neovascularization; Subcutaneous Space; Type 1 Diabetes
Abstract
Islet cell transplantation to treat type 1 diabetes has been proven to be a viable and effective method to establish normal blood glucose levels in patients. However, an issue faced with islet cell transplantation is that the standard practice of infusing the cells into liver leads to gradual deterioration of the graft. Additionally, islet cells transplanted into the liver are difficult to recover and monitor after surgery. Once transplanted, the islet cells face the inflammatory and adaptive immune response from the host body. Hence, recipients of islet cell transplantation must undergo lifelong immunosuppression. A subcutaneous transplant site (under the skin) is appealing due to its non-invasive nature and being easily accessible for post-transplant monitoring. A subcutaneous device-less (DL) transplant method has been developed to precondition the transplant site by improving the vascularization and reducing inflammation to make the environment more favourable for the islet cells. An approach being investigated to tackle the issue of systemic immunosuppression after transplantation is the localized delivery of drugs through polymer-derived microspheres. These microspheres allow for the localized delivery of a desired drug and allows for a gradual release due to its biocompatibility and biodegradable properties. The project aims to develop a subcutaneous transplantation site that is immuno-suppressive free through the use of the device-less method and microspheres. Further testing will be done to evaluate the efficacy of other drugs and possible drug combinations. If proven effective the subcutaneous transplant site and microspheres together could eliminate the need for systemic immunosuppression and allow for better function and monitoring of the graft.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ma, Ivan J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~